Î÷¹ÏÊÓƵ

[Skip to Navigation]
Sign In

September 2024 - January 1920

Decade

Year

Issue

March 2024, Vol 160, No. 3, Pages 259-372

Editorial

The Promise and Drawbacks of Federated Learning for Dermatology AI

Abstract Full Text
free access
JAMA Dermatol. 2024;160(3):269-270. doi:10.1001/jamadermatol.2023.5410

Clinical Data on Laboratory Testing for Patients Taking Systemic Immunomodulatory Agents: Do We Order Them Enough or Too Much?

Abstract Full Text
JAMA Dermatol. 2024;160(3):271-272. doi:10.1001/jamadermatol.2023.5891
Original Investigation

Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials

Abstract Full Text
JAMA Dermatol. 2024;160(3):281-289. doi:10.1001/jamadermatol.2023.5509

This systematic review with meta-analysis examines the risk of major adverse cardiovascular events, venous thromboembolism, serious adverse events, and tolerability of systemic Janus kinase–signal transducer and activation of transcription (JAK-STAT) compared with placebo in those with a dermatologic indication.

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial

Abstract Full Text
JAMA Dermatol. 2024;160(3):290-296. doi:10.1001/jamadermatol.2023.5679

This cohort study using follow-up data from the Ritux 3 randomized clinical trial examines the association of rituximab treatment with long-term complete remission without corticosteroid therapy when used as first-line treatment for patients with pemphigus.

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

Abstract Full Text
JAMA Dermatol. 2024;160(3):297-302. doi:10.1001/jamadermatol.2023.5857

This economic evaluation estimates US spending on beremagene geperpavec for treating dystrophic epidermolysis bullosa under varying assumptions of cost, the eligible patient population, patient age at diagnosis, and life expectancy.

Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics

Abstract Full Text
open access
JAMA Dermatol. 2024;160(3):303-311. doi:10.1001/jamadermatol.2023.5550

This diagnostic study investigates the performance of a privacy-preserving federated learning approach vs a classical centralized and ensemble learning approach for artificial intelligence–based melanoma diagnostics.

Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa

Abstract Full Text
has audio
JAMA Dermatol. 2024;160(3):312-318. doi:10.1001/jamadermatol.2023.6201

This cohort study investigates the optimal course duration, efficacy, and patient satisfaction associated with intravenous ertapenem treatment for hidradenitis suppurativa.

Brief Report

Retrospective Case Series of Cocaine-Associated Plasma Cell Orificial Mucositis

Abstract Full Text
JAMA Dermatol. 2024;160(3):320-327. doi:10.1001/jamadermatol.2023.5692

This case series establishes the clinicopathological characteristics of plasma cell orificial mucositis.

Clinical Features and Outcomes of Black Patients With Melanoma

Abstract Full Text
JAMA Dermatol. 2024;160(3):328-333. doi:10.1001/jamadermatol.2023.5789

This case series identifies patient-level and tumor-level characteristics of melanoma in 48 Black patients at 2 tertiary care centers.

Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases

Abstract Full Text
JAMA Dermatol. 2024;160(3):334-340. doi:10.1001/jamadermatol.2023.5895

This descriptive analysis aims to determine the prevalence of pretreatment testing that is recommended for patients with chronic inflammatory skin diseases (psoriasis, hidradenitis suppurativa, or atopic dermatitis).

Editor's Note

Balancing Ertapenem Therapy in Recalcitrant Hidradenitis Suppurativa With Antibiotic Stewardship

Abstract Full Text
JAMA Dermatol. 2024;160(3):319. doi:10.1001/jamadermatol.2023.6197
Consensus Statement

The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(3):341-350. doi:10.1001/jamadermatol.2023.5869

This preliminary global consensus survey study identifies factors associated with alopecia areata severity beyond scalp hair loss, supporting the development of a multicomponent severity tool that would successfully measure various disease outcomes.

Images in Dermatology

Papular Mucinosis

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(3):351. doi:10.1001/jamadermatol.2023.4976

This case report describes erythematous patches on the face that involved the nasolabial folds, as well as numerous skin-colored homogenous waxy papules on the arms, neck, and trunk.

Erythrasma

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(3):352-353. doi:10.1001/jamadermatol.2023.5129

This case report describes well-demarcated brown plaques with overlying fine scale in the bilateral axillae, inframammary folds, and inguinal folds and widespread coral-red fluorescence.

JAMA Dermatology Clinicopathological Challenge

Segmental Skin Induration in a Boy

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(3):354-355. doi:10.1001/jamadermatol.2023.4235

An 11-year-old boy presented with progressive unilateral skin hardening on his right thigh and buttock for 7 years. What is your diagnosis?

Annular Erythematous Plaques With Overlying Blisters in a Cluster of Jewels Pattern

Abstract Full Text
has active quiz
JAMA Dermatol. 2024;160(3):356-357. doi:10.1001/jamadermatol.2023.4461

A woman in her 80s presented with erythematous, nondesquamative, annular plaques in a cluster of jewels pattern on her wrists and legs. What is your diagnosis?

JAMA Dermatology Patient Page

Alopecia Areata

Abstract Full Text
free access
JAMA Dermatol. 2024;160(3):372. doi:10.1001/jamadermatol.2023.4661

This Patient Page describes the symptoms, diagnosis, and treatment of alopecia areata.

Research Letter

Support Group Participation Among Patients With Alopecia Areata

Abstract Full Text
JAMA Dermatol. 2024;160(3):358-360. doi:10.1001/jamadermatol.2023.6037

This cross-sectional study describes support group use and experience among patients with alopecia areata.

Perspectives on Full-Body Skin Examinations Among Sexual and Gender Minority Patients

Abstract Full Text
JAMA Dermatol. 2024;160(3):361-363. doi:10.1001/jamadermatol.2023.5821

This survey study assesses full-body skin examination rates among sexual and gender minority patients and investigates their comfort with and reasons for discomfort during these examinations.

Observation

Ruxolitinib for Refractory PL-12 Antisynthetase Syndrome–Associated Angioedema-Like Panniculitis With Clonal T-Cell Receptor Gene Rearrangement

Abstract Full Text
JAMA Dermatol. 2024;160(3):363-366. doi:10.1001/jamadermatol.2023.4940

This case report describes a woman in her 30s who presented with a 3-year history of anti–PL-12 antisynthetase syndrome characterized by interstitial lung disease, arthritis, and myositis and was diagnosed with antisynthetase syndrome–associated panniculitis.

Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1

Abstract Full Text
JAMA Dermatol. 2024;160(3):366-368. doi:10.1001/jamadermatol.2023.5338

This case report describes 4 patients with a rare autosomal dominant multisystem disorder resulting from NF1 variants that leads to café-au-lait macules and neurofibromas.

Comment & Response

Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment

Abstract Full Text
JAMA Dermatol. 2024;160(3):368-369. doi:10.1001/jamadermatol.2023.5594

Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment—Reply

Abstract Full Text
JAMA Dermatol. 2024;160(3):369-370. doi:10.1001/jamadermatol.2023.5583

Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis

Abstract Full Text
JAMA Dermatol. 2024;160(3):370. doi:10.1001/jamadermatol.2023.6198
Correction

Errors in Abstract, Results, Tables, and Figures

Abstract Full Text
free access
JAMA Dermatol. 2024;160(3):370. doi:10.1001/jamadermatol.2023.6395

Error in Table

Abstract Full Text
free access
JAMA Dermatol. 2024;160(3):370. doi:10.1001/jamadermatol.2023.6260

Error in Byline

Abstract Full Text
free access
JAMA Dermatol. 2024;160(3):370. doi:10.1001/jamadermatol.2023.6175
JAMA Dermatology Masthead

JAMA Dermatology

Abstract Full Text
free access
JAMA Dermatol. 2024;160(3):259. doi:10.1001/jamadermatol.2023.3976
×